PITTSBURGH, May 29, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that Raymond Vennare, Chief Executive Officer, is scheduled to deliver a company overview presentation at the BIO International Convention 2024, which is being held June 3-6 in San Diego. "We are very pleased to participate in this year's Bio International Convention, which is the premier gathering of biopharmaceutical stakeholders from around the world," ...

During the conference, Prashant Kohli, Chief Executive Officer of Acasti, will host meetings with pharmaceutical executives to explore partnership and strategic opportunities for the Company's asset portfolio. To connect during the conference, please request a meeting via the BIO International meeting portal or contact mmoyer@lifesciadvisors.com. PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its ...

WALL, N.J., May 24, 2024 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB), announced today that on May 22, 2024, it received a letter (the "Notification Letter") from The Nasdaq Stock Market, LLC ("Nasdaq") informing the Company that it was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required per ...

MINNEAPOLIS, May 22, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced continued technical and clinical collaboration following release of Regulus' positive topline results from the second cohort of patients in its Phase 1b MAD (multiple ascending dose) study of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADP ...

BOCA RATON, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) (Nasdaq: ENTO) ("Entero" or the "Company"), a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it will present at the 2024 BIO International Convention which will be held June 3-6, 2024, in San Diego, California. Event: BIO International Convention Date: June 3-6, 2024 Presentati ...

HOLMDEL, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) solutions featuring passwordless, phoneless and token-less Identity-Bound Biometric (IBB) authentication, today announced that it currently expects to file its audited 2023 results with the SEC on Form 10-K next week. BIO-key also expects to report its Q1 2024 results and hold an investor call by the end of next week. The Company w ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-07928 Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject ...

Bio-Rad Laboratories, Inc. (BIO) posted first-quarter 2024 adjusted earnings per share (EPS) of $2.29, beating the Zacks Consensus Estimate by 12.3%. However, the bottom line declined 31.4% from the prior-year quarter’s levels.The quarter’s adjustments eliminate the impacts of certain non-recurring items like the amortization of purchased intangibles, Restructuring costs, gains/losses from the change in the fair market value of equity securities and gains/losses on equity-method investments.The company’s GA ...

财务数据和关键指标变化 - 第一季度收入为6.11亿美元,同比下降9.8% [28] - 生命科学业务收入为2.42亿美元,同比下降25.3% [29] - 临床诊断业务收入为3.69亿美元,同比增长4.7% [30] - 毛利率为53.4%,与上年同期持平 [32] - 非GAAP毛利率为54.2%,与上年同期持平 [40] - 非GAAP营业利润率为9.7%,同比下降2.7个百分点 [43] 各条业务线数据和关键指标变化 - 生命科学业务中,除过程色谱销售外,其他产品线收入同比下降16.6% [29] - 过程色谱销售大幅下滑,公司预计全年将进一步下降 [19][20] - 临床诊断业务各地区均实现增长,尤其是EMEA和亚太地区 [31] 各个市场数据和关键指标变化 - 中国市场生命科学业务持续疲软,但政府刺激政策令公司对长期复苏持乐观态度 [25] - 俄罗斯市场公司继续维持关键临床诊断产品的供应 [25] - 美国NIH预算延迟批准,最终水平略低于预期 [26] - 欧洲主要市场政府资金情况参差不齐,德国下降,英法基本持平 [26] 公司战略和发展方向及行业竞争 - 公司保持生命科学和诊断两大业务的长期发展战略不变 [53][54][55] - 在生命科学领域,公司将继续投资发展数字PCR等领先平台,并拓展到细胞生物学等新领域 [54][55] - 在诊断业务,公司将继续巩固核心诊断平台的市场地位,并通过PCR One等新技术进军分子诊断市场 [54] - 公司认为生命科学和诊断业务长期增长前景良好,能够度过当前动荡时期 [55] 管理层对经营环境和未来前景的评论 - 宏观经济和市场环境与公司预期基本一致 [18][24][26] - 生命科学市场复苏的时间和幅度仍存在不确定性,但有望在下半年改善 [26][50] - 诊断业务预计将保持正常增长 [26][50] - 公司维持全年收入增长1-2.5%,非GAAP营业利润率13.5%-14%的指引 [51] 问答环节重要的提问和回答 问题1 **Patrick Donnelly 提问** 询问生命科学业务在全年指引中的表现预期 [57][58][59][60] **Andy Last 回答** 过程色谱销售疲软是导致生命科学业务下滑的主要原因,但核心业务表现符合预期,公司维持全年指引 [58][59][60][62] 问题2 **Selena Lu 提问** 询问对下半年业务恢复的信心和Q2的预期 [67][68][69][70] **Andy Last 回答** 需要看到资金流入转化为订单,才能确定下半年恢复,Q2仍存在不确定性 [68][70] 问题3 **Conor McNamara 提问** 询问数字PCR业务合作对公司收入的影响 [88][89][90] **Andy Last 回答** 这些合作项目短期内不会产生重大收入影响,但从长远来看有助于拓展数字PCR在临床诊断领域的应用 [88][89][90]

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.29 per share, beating the Zacks Consensus Estimate of $2.04 per share. This compares to earnings of $3.34 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 12.25%. A quarter ago, it was expected that this maker of instruments used in biomedical research would post earnings of $2.93 per share when it actually produced earnings of $3.10, delivering a surprise of 5.8 ...